Background: Despite Côte d'Ivoire epidemic being labeled as "generalized," key populations (KPs) are important to overall transmission. Using a dynamic model of HIV transmission, we previously estimated the impact of several treatment-as-prevention strategies that reached-or missed-the UNAIDS 90-90-90 targets in different populations groups, including KP and clients of female sex workers (CFSWs). To inform program planning and resources allocation, we assessed the cost-effectiveness of these scenarios.
INTRODUCTION
HIV control program managers face difficult decisions regarding whether, and to what extent, specific populations should be prioritized when allocating budget for prevention and treatment. HIV epidemics have traditionally been classified as "generalized" when HIV prevalence reached 1% or more among all reproductive-aged adults and as "concentrated" if prevalence does not meet this threshold but is disproportionately higher among key subgroups of the population. 1 Evidence now suggests that allocating resources to specific population groups based on this dichotomy can be misleading. [2] [3] [4] In Côte d'Ivoire, where overall prevalence was 3.7% in 2011-2012, 5 key populations (KPs) such as female sex workers (FSWs) and men who have sex with men (MSM), along with clients of FSWs (CFSWs), are highly vulnerable to HIV infection, and the intervention gaps are such that they are important to overall transmission dynamics, despite the epidemic being characterized as "generalized". 6, 7 This could have important practical implications for resources allocation of HIV prevention programs.
With an estimated 460,000 people living with HIV (PLHIV) in 2016, Côte d'Ivoire has among the highest burden of HIV across West Africa. 8 Eliminating HIV and AIDS as a public health threat by 2030, the objective put forward by the Joint United Nations Programs on HIV/AIDS (UNAIDS) will require the rapid strengthening of the HIV treatment and care continuum. 9 This 90-90-90 target calls for 90% of PLHIV to be aware of their status, 90% of those diagnosed to receive antiretroviral therapy (ART), and for 90% of those on treatment to have a suppressed viral load by 2020, with each of these 3 targets reaching 95% by 2030. Previous modeling results, based on a dynamic mathematical model of sexual HIV transmission in Côte d'Ivoire, 10 suggest that, along swift increases in HIV testing, sustaining core group interventions aimed at those KP could be crucial to maximizing the number of HIV infections averted. This poses significant economic challenges, however, because the demand for financial resources to reach this objective are increasing and foreign government assistance for HIV in low-and middle-income countries has declined in recent years. 11 Decision-makers often aim to maximize the population-level impact of programs while constraining expansion of health budgets. They are faced with numerous programmatic choices about what type of interventions to prioritize (HIV testing, linkage to care, ART initiation, adherence, etc.), the population groups to target (general population, FSW, CFSW, MSM, etc.), and the speed at which program components need to be scaled-up. Furthermore, the population-level impact of those programs should be evaluated over the long-term to take into account the benefits of averting long chains of transmission that accrue with time (ie, indirect benefits). 4 Dynamic models of HIV transmission then become a useful tool to perform an economic evaluation of many competing programmatic decisions that could not be empirically tested before implementation of HIV prevention programs.
The overall objective of this study is to inform program planning and resources allocation in Côte d'Ivoire. To this end, we performed a model-based economic evaluation of 10 previously described treatment-as-prevention scenarios, 10 while accounting for uncertainty in both impact and cost estimates. Incremental cost-effectiveness ratios (ICERS) are expressed both per new HIV infection prevented and per disability-adjusted life-years (DALYs) averted, the latter metric combining morbidity and mortality.
METHODS

Overview
The changes in population health that would result from implementation of accelerated HIV response scenarios were estimated using a dynamic model of HIV transmission, parameterized and calibrated to local epidemiological data. 6, 7, 10 Briefly, this model is stratified in 4 age groups (15-19, 20-24, 25-49 , and 50-59 years old) and 6 risk groups: low-risk female, high-risk females (non-FSW with .1 partner year 21 ), FSW, low-risk males, high-risk males (non-CFSW with .2 partners year 21 ), CFSW, and MSM. It considers natural disease progression and the treatment and care continuum. We estimated the ICER of 9 HIV treatmentas-prevention scenarios in Côte d'Ivoire over the 2015-2030 period, by comparing it with our baseline scenario (SC1) that maintains 2015 levels of HIV testing rates, ART initiation rates, ART failures, ART discontinuation rates, coverage of prevention of mother-to-child transmission (PMTCT) activities, and levels of condom use. Although ICER are often calculated sequentially, from least effective to most effective, each scenario is compared with the baseline one in this study. This decision was motivated by considering the interpretability and comparability of different policy options. ICER are calculated by dividing the difference in programs' costs by their population-level effectiveness differential (ICER = Dcosts / Dimpact ). These 10 simulated scenarios, which can be broadly categorized as those without (scenarios 2-6) and with specific prioritization of interventions targeting FSW, MSM, and/or CFSW (scenarios 7-10), have been previously presented and analyzed. 10 For convenience, these are summarized in Table 1 .
Epidemiological Modeling: HIV Infections and Disability-Adjusted Life-Years Averted HIV infections averted were measured by estimating the number of new HIV infections averted, as compared to the baseline scenario. The years of life lost (YLL) component of DALYs was calculated from the model's predicted number of AIDS-related deaths among the 15-59 years old. 10 The mean age at death within the 4 age classes was estimated from the age-specific AIDS-related death rates ( Table 2) . We then obtained the YLL by subtracting the median age of AIDS deaths from the remaining life expectancy at that age, as obtained from the United Nations population projections for Côte d'Ivoire. 12 Morbidity was assessed by quantifying the number of person-years lived in 4 mutually exclusive HIV/ AIDS stages: early HIV (diagnosed individuals with CD4 + count .350 cells/mL, untreated), pre-AIDS symptomatic (CD4 + cell count 200-349 cells/mL, untreated and irrespective of diagnosis status), AIDS (CD4 + cell count ,200 cells/ mL, untreated), and those on ART (regardless of CD4 + cell count). The person-time in each stage was then associated with its corresponding disability weight from the Global Burden of Disease study 13 to estimate YLL due to disability (Table 2) . Finally, the number of DALYs averted was calculated by combining YLL and years of life lived with disability for each scenario, as compared to the baseline one.
In accordance with the methodology adopted by the Global Burden of Disease, health outcomes were not discounted and age-weighting was not implemented. Sensitivity analyses were performed where health outcomes were discounted at 3%.
Costing of Activities
We estimated the programmatic costs of the different HIV response scenarios from the provider's perspective (ie, the Ivorian Ministry of Health) using an ingredient approach. 14 Our main data source consists of the unit costs reported by the Ivorian Programme national de lutte contre le Sida (PNLS). This was supplemented by reviewing economic evaluations conducted in Côte d'Ivoire and, if unavailable, elsewhere in sub-Saharan Africa. The main unit costs used are presented in Table 3 . Full details of the reviewed documents are presented as supplementary materials. For each scenario, we included the following main programmatic components: voluntary counseling and testing (see Table S1 , Supplemental Digital Content, http://links.lww.com/QAI/B272), pre-ART evaluation and ART (see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/B272), PMTCT services (see Table S3 , Supplemental Digital Content, http://links. lww.com/QAI/B272), laboratory testing for those on ART (CD4 + cell count, viral load, and routine tests) (see Table S4 , Supplemental Digital Content, http://links.lww.com/QAI/ B272), ART adherence support (see Table S5 , Supplemental Digital Content, http://links.lww.com/QAI/B272), and male condom provision and distribution for KP (see Table S6 , Supplemental Digital Content, http://links.lww.com/QAI/ B272). Whenever appropriate, different unit costs were used for the general population, MSM, FSW, and CFSWreflecting the different needs and challenges in reaching these groups. Furthermore, our estimates of unit costs considered (if applicable) the opportunity costs of existing inputs such as personnel time. All unit costs were converted from local currency to 2015 US Dollar (USD) using the average exchange rate for that year and, subsequently, appropriate gross domestic product deflator. 15 The economic evaluation spans the 2015-2030 period. Total program costs were calculated by multiplying the unit costs by the number of units required, as informed by the mathematical model, 6, 7, 10 and using a 3% discount rate. Population growth was assumed to be 3.2% over the 2015-2030 period.
These budget calculations include the activities that were deemed important to the incremental costs of accelerating the HIV response. We do not include all HIV/AIDS services and assumed that the health system has the capacity to scale-up its response without further infrastructure investments.
Provider's Resources Savings
Preventing new adult HIV infections could have important downstream positive budgetary consequences, and we calculated both gross and net ICER. Cost savings to the provider that would result from preventing new HIV infections were estimated by considering pre-ART evaluation costs (once, at linkage), and annual treatment and adherence support costs (see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/B272). For each infection averted, cost savings accrue from the date of infection to age 60 (upper age limit in the compartmental model) or the 2030 calendar year, whichever occur first. The average age at HIV infection within our 4 age groups was estimated based on the age-and scenario-specific incidence rates. We implicitly assumed that diagnosis and treatment would occur within a year of the infection when calculating cost savings per new HIV infection averted, and that all new people infected with HIV would receive treatment. Provider's cost savings were also discounted at a 3% rate. Net ICER were calculated by subtracting resources savings from total incremental program costs for each scenario.
Probabilistic Sensitivity Analysis
We conducted a probabilistic sensitivity analysis to examine the impact of uncertainty on the cost of HIV prevention and treatment services and on the effectiveness estimates (infection and DALY averted). We performed 10,000 Monte Carlo simulations by sampling costs parameters and disability weighs from their elicited distributions (see Table S7 , Supplemental Digital Content, http://links.lww. com/QAI/B272). Uncertainty in the effectiveness estimates of the scenarios and population denominators (ie, number of HIV test needed, number on ART, size of KP, etc.) was considered by sampling these from the mathematical model's posterior distributions. 10 We used 90% uncertainty intervals (90% UI) with the median of the probabilistic sensitivity analyses corresponding to point estimates.
RESULTS
Budget Requirements for the Activities Included in the Costing
The average annual budget of the baseline scenario (SC1), for the activities included in the costing, would be of $61 M (90% UI: $51-$74 M), the lowest of all scenarios examined (Fig. 1) . Approximately 48% of the costs would be allocated to treatment, 20% to testing, 14% to laboratory services (including pre-ART evaluation), 12% to condoms for KP, and 6% for PMTCT. The least affordable scenario is the one where the UNAIDS targets are met, and condom use is increased among KP (SC9; average annual budget of $152 M; 95% UI: $128-$173 M). It is followed by the UNAIDS scenario (SC3; average annual budget of $149 M; 90% UI: $126-$170 M) and the UNAIDS scenario with condom use decrease among KP (SC10; average annual budget of $150 M; 90% UI: $125-$170 M). The bulk of the costs of accelerating the HIV response is due to HIV testing (Fig. 1) . In comparison, the difference in HIV treatment costs between the baseline scenario and the UNAIDS one (SC3) is roughly Table S3 Laboratory tests when on ART (patientyear 21 ) $28.13 Table S4 ART adherence and support Per in-need PLHIV on ART year 21 † $38.56 Table S5  Condoms Per male condom for FSW and MSM $0.49 Table S6 *Most unit costs were obtained from the Ivorian Programme national de lutte contre le Sida. If unavailable, the median unit costs from other economic evaluations conducted in Côte d'Ivoire (or sub-Saharan Africa) were used. Costs include disposables and personnel time.
†For budget calculations, ART adherence and support are required for 25% of PLHIV in the general population and for 50% of PLHIV who are MSM or FSW. $10 M. The 3 most affordable scenarios, beside the baseline scenario, are those of the scenarios that maintain current trend (SC2; average annual budget of $72 M; 90% UI: $59-$88 M), the scenario that achieves the UNAIDS targets in KP only (SC7; $69 M; 90% UI: $56-$81 M), and the one that also achieves it in CFSW (SC8; $83 M; 90% UI: $67-$100 M).
Review of the Population-Level Impact of the Scenarios
An in-depth presentation of the epidemiological impact of the scenarios has been previously published. 10 Briefly, compared with the baseline scenario, the scenario that had the biggest population-level impact over 2015-2030 was the one where the UNAIDS 90-90-90 targets are attained in 2020 (and 95-95-95 in 2030) and where the proportion of sex acts protected by a condom reaches 95% among KP (SC9), with a prevented fraction (PF) of 53% of new HIV infections (Table 1) . Without increases in condom use among KP (SC3), the same scenario would still avert 50% of new infections, mainly because condom use is already high among FSW and MSM. The 2 scenarios that are predicted to prevent the smallest fraction of new HIV infections were those that maintain current trends in program scale-up (SC2; PF = 11%), and the one where UNAIDS targets are attained only among KP (SC7; PF = 9%). Other scenarios include the following: reaching the UNAIDS objective with a 5-year delay (SC4; PF = 30%), realizing the 90-90-90 objective but missing the 95-95-95 target (SC5; PF = 42%), reaching the UNAIDS objective only among the general population and not among KP (SC6; PF = 45%), reaching the UNAIDS objective among KP and CFSW (SC8; PF = 30%), and achieving the UNAIDS targets but reducing condom use by 25% point among KP (SC10; PF = 38%).
Incremental Cost-Effectiveness Ratios per HIV Infection Prevented
The 2 scenarios with the smallest epidemiological impact are among the most cost-effective ones ( Table 4) . The gross ICER per HIV infection prevented is estimated at $3500 and $2700 for the current trends (SC2) and the UNAIDS in KP scenarios (SC7), respectively ( Table 4) . The most cost-effective one, however, is the scenario where the UNAIDS targets are reached in KP and CFSW (SC8; ICER = $2600). Reaching the UNAIDS targets (SC3) had an ICER of $6700 per infection averted. There seems to be some diminishing returns of reaching the 95-95-95 objective by 2030 as the UNAIDS scenarios that maintain its 90-90-90 target over the 2020-2030 period was found to be more costeffective (SC5; ICER = $5400). The least cost-effective is the UNAIDS scenario with condom decreases among KP (SC10), with a gross ICER per HIV infection prevented of $8800.
The cost-effectiveness ranking of the scenarios remained unchanged when also considering provider's resource savings, with the scenario that achieves the UNAIDS target in KP and CFSW being the most cost-effective (net ICER = $1200). The cost-effectiveness planes for net costs and HIV infection prevented show a high amount of uncertainty for both net costs and outcomes (Fig. 2) .
Incremental Cost-Effectiveness Ratios per DALY Averted
Gross ICER per DALY averted ranged between $300 (SC2) and $820 (SC10). Expressing the gross ICER per DALY averted influenced the ranking of the most costeffective intervention, with the current trend scenarios (SC2; ICER = $300; 90% UI: $230-$400) being more cost-effective than the scenario that reaches the UNAIDS target in KP and CFSW (SC8; ICER = $400; 90% UI: $250-$700).
Again, the least cost-effective scenario was the one where the UNAIDS target is attained but accompanied in decreases in condom use among KP (SC10) with a gross ICER of $820 per DALY averted ( Fig. 3 and Table 4 ). It is followed closely by 3 scenarios, those where the UNAIDS target is only reached in the general population (SC6; ICER = $710), the UNAIDS scenario (SC3; ICER = $700), and the UNAIDS scenario with condom increases in KP (SC9; ICER = $690). Considering resources savings, the 2 most costeffective scenarios were almost indistinguishable ( Fig. 3) : the current trend scenario (SC2) had a net ICER of $210 per DALY averted (90% UI: $150-$300), whereas the UNAIDS in KP and CFSW (SC8) had a net ICER of $220 per DALY averted (90% UI: $80-$660). As such, the specific ranking of the scenarios should be interpreted considering their relatively wide uncertainty intervals of the point estimates (Fig. 3) . For example, the 3 most cost-effective scenarios (SC2, SC7, and SC8) all ranked between the first and the third positions for 90% of simulations (Table 4) . Importantly, the least cost-effective scenarios (UN-AIDS with condom drop, SC10) has a net ICER of $710 per DALY averted. This is well below Côte d'Ivoire's per capita gross domestic product of $1435 in 2015 15 , which has been proposed by the World Health Organization as a threshold to qualify interventions as very cost-effective. 16, 17 Indeed, all scenarios investigated are likely to be very cost-effective (Fig. 4) .
ICER with health outcomes discounted at 3% are presented as supplementary material (see Table S8 , Supplemental Digital Content, http://links.lww.com/QAI/B272). These additional analyses suggest that discounting health outcomes does not affect either the ranking of the scenarios or our finding that all scenarios have a high probability of being cost-effective.
DISCUSSION
Achieving the UNAIDS 90-90-90 objective in Côte d'Ivoire and elsewhere will require the mobilization of important financial resources. 18 The economic evaluation shown here demonstrates that further scale-up of the HIV response is cost-effective. Indeed, all investigated scenarios were found to be very cost-effective according to commonly used thresholds. Importantly, some very cost-effective scenarios, with large epidemiological impacts, seem unaffordable given Côte d'Ivoire's health budget of $670 M for the year 2018. 19 For example, the UNAIDS scenario (SC3) would require increasing the national health budget by roughly 11%-14%. By contrast, reaching the UNAIDS targets among KP and CFSW (SC8) would require additional investments corresponding to 1%-2% of the current budget. Programmatic decisions regarding resources allocation should consider affordability, cost-effectiveness, and epidemiological impact (Fig. 5) . 20 Reaching the UNAIDS scenario among KP and CFSW therefore seems to be a promising avenue because it has a much larger epidemiological impact than the other 2 scenarios that were found to be most cost-effective.
Our findings are in line with previous results that reflect the epidemiological importance of MSM, FSW, and CFSW to overall HIV transmission in Côte d'Ivoire. 6 Furthermore, the least cost-effective scenario was the one where the UNAIDS target was met but accompanied by a 25% point drop in the proportion of sex acts protected by condoms for both FSW and MSM. At a time where Côte d'Ivoire has experienced funding cutbacks for KP programs, 21 our results-along with those from other studies 3, [22] [23] [24] [25] [26] -emphasize the relevance of sustaining condom use and core groups interventions in this West African country and other ones in the region.
Financing KP activities might prove difficult to sustain in the future, however. Currently in Côte d'Ivoire, 91% of the annual HIV budget is funded by the U.S. President Emergency Fund for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis and Malaria. 27 This high share of global financing for HIV makes Côte d'Ivoire vulnerable to potential funding contractions from these organizations. In fact, if domestic budgets are not increased to offset such reductions, Côte d'Ivoire could suffer "HIV epidemic revival and massive loss of life". 28, 29 Although we did not examine the impact of potential budget contractions on the course of the HIV epidemic, our results suggest that maintaining funding for core groups interventions could potentially mitigate, at least partly, such catastrophic scenarios.
Further comparisons with other economic evaluations of accelerated HIV response programs in sub-Saharan Africa are difficult for several reasons. First, there are important variations in the chosen baseline scenarios. Second, models used to estimate effectiveness of interventions are not always dynamic and do not capture important indirect effects (ie, averting chains of transmission). Third, models vary widely in their assumptions, such as the adopted perspective, time horizon, discounting of health outcomes, and programmatic needs. What is clear, however, is that numerous economic evaluations have shown that fast tracking the HIV response is likely cost-effective across sub-Saharan Africa. 18, 26, 30 To materialize these health gains, however, not only will substantial financial resources be needed, but also program efficiency will matter. Notably, important obstacles will need to be overcome from structural barriers to high HIV testing uptake, 31, 32 suboptimal linkage to care, 33, 34 and poor ART adherence. 35 These barriers might be more pronounced and difficult to overcome for KP. Furthermore, efficiently reaching CFSW might prove challenging, 36 but several strategies exist to do so, from peer education programs to targeted behavioral interventions. [37] [38] [39] [40] Our results suggest that interventions to increase HIV testing and linkage to care should be further investigated, and the successful ones implemented at scale for the HIV response to be sustainable.
The results from our economic evaluation should be interpreted considering several methodological limitations. First, we did not consider cost functions (economies of scales) given the paucity of information on this topic. Second, we assumed that sexual and risk behaviors would stay constant, a challengeable but reasonable assumption given our 15-year time horizon. Third, we assumed that the Ivorian health system had the capacity to scale-up its HIV response without the need for further infrastructure investments, such as building new dispensaries, health centers, or laboratories. Fourth, our dynamic model of HIV transmission represents transmission at the national level, whereas geographical HIV risk varies by region in Côte d'Ivoire. Our analyses also assume uniform geographical program coverage such that the cost-effectiveness of spatially targeted intervention could not be investigated but could improve cost-effectiveness. 22, 41 Fifth, we did not include pediatric outcomes in our economic evaluation because our model does not longitudinally follow disease progression in infants, hereby underestimating costeffectiveness. Finally, we found that an important determinant of the scenarios' budgetary requirements was that of HIV testing. The model assumed that the baseline testing rates in the different risk and age groups would be proportionally scaled up to a maximum rate of once a year for the general population and 4 times a year for FSW and MSM. Potential increases in the efficiency of testing services were not considered (eg, by increasing yield of new HIV diagnoses through contact tracing). Hence, we could have overestimated ICER of some of the scenarios. We conducted a sensitivity analysis where we posited that the required number of HIV tests in the general population would be 50% of the modelpredicted requirements from 2020 onwards-implicitly assuming that yield of new diagnoses could be doubledfor the UNAIDS scenarios not prioritizing KP (see Table S9 , Supplemental Digital Content, http://links.lww.com/QAI/ B272). Doing so, our finding that accelerating the HIV response in Côte d'Ivoire is likely very cost-effective remains valid, but with larger uncertainty and improved affordability and cost-effectiveness of UNAIDS scenarios not prioritizing KP.
The strengths of our study include the use of a detailed dynamic model of HIV transmission, parameterized and calibrated to local epidemiological and programmatic data. 6, 7, 10 This model considers the indirect benefits of averting chains of transmission over the long term. We conducted a detailed cost analysis and included relevant unit costs from the Ivorian Programme national de lutte contre le Sida. Furthermore, we incorporated uncertainty in both impact and cost estimates through probabilistic sensitivity analyses.
CONCLUSIONS
Our analyses of different accelerated HIV response scenarios in Côte d'Ivoire highlight important tensions between dimensions of affordability, cost-effectiveness, and epidemiological impact. These issues are compounded by challenges in rallying political support for responses that target members of KP given that these HIV-vulnerable KP are often heavily stigmatized. The findings presented here are nevertheless central to devise informed health policies. These should be improved and supported through a better understanding of population-level risk distribution and changing transmission dynamics. In conclusion, sustaining high condom use and levels of viral suppression among MSM, FSW, and CFSW seems the most affordable and cost-effective scenario, while averting a reasonable number of DALYs. These results were found to be robust to modeling and costing assumptions.
